Key clinical point: While African Americans with acute myeloid leukemia (AML) were more likely to have evidence of abnormal kidney function, this didn’t affect overall survival, compared with whites.
Major finding: Median overall survival was 13.7 months for African Americans and 14.9 months for whites (P = 0.89).
Study details: Retrospective study of 1,040 AML patients who received chemotherapy at Cleveland Clinic between 2003 and 2019.
Disclosures: Study authors provided disclosures related to Amgen, SimulStat, Bristol-Myers Squibb, Takeda, Pfizer, Novartis, Celgene Corporation, Abbvie, and Incyte, among others.
Statler A et al. ASH 2019, Abstract 381.